Clinical trials: Atopic Disorders
Atopic Dermatitis
Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis
This is a Phase 2b, multi-center, randomized, double-blind, vehicle-controlled, intraparticipant study to evaluate efficacy and safety of two regimens of crisaborole ointment 2% in Japanese pediatric and adult participants…
- Trial name
- NCT03954158
- Testing
- Crisaborole ointment 2%, Vehicle
- Where
- 3 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Pfizer
Food Allergy
Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis
This study evaluates the effectiveness of Dupilumab in food allergic patients with moderate to severe Atopic Dermatitis (AD). Included patients participated in the BioDay Registry.
- Trial name
- NCT04462055
- Where
- Netherlands
- Volunteers
- 3 people
- Sponsor
- UMC Utrecht
Atopic Dermatitis, Eczema, Atopic
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
The goal of this clinical trial is to compare a step-down strategy of spacing dupilumab injections with a standard maintenance treatment in adolescents and adults with controlled Atopic dermatitis (AD) for at least six months.
- Trial name
- MADULO (NCT05642208)
- Testing
- Dupilumab step-down
- Where
- 32 sites in France, Reunion
- Volunteers
- 256 people
- Sponsor
- Nantes University Hospital
Dermatitis Atopic
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant…
- Trial name
- GLOBOSTAD (NCT03992417)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 105 sites in Argentina, Australia and 20 more
- Volunteers
- 955 people
- Sponsor
- Sanofi
Atopic Dermatitis
Effectiveness of a Combined Dermatological Treatment in Children With Atopic Dermatitis
The purpose of this study is to determine the effectiveness of a combined dermatological treatment in children up to 5 years old with mild or moderated atopic dermatitis.
- Trial name
- KAOS (NCT02920411)
- Testing
- Pediatopic Treatment Cream, Pediatopic Body lotion
- Where
- 2 sites in Spain
- Volunteers
- 43 people
- Sponsor
- Laboratorios Ordesa
Childhood Atopic Dermatitis
Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis
Patients with atopic dermatitis treated with conventional treatment plus Dialyzed Leukocyte Extracts (DLE-oral Transferon) as adjuvant, have better clinical outcome than patients treated only with conventional treatment.
- Trial name
- NCT01902836
- Testing
- Conventional treatment plus DLE
- Where
- Mexico
- Volunteers
- 58 people
- Sponsor
- National Polytechnic Institute, Mexico
Dermatitis, Atopic
Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)
The purpose of this study was to test the effectiveness and safety of desloratadine (Aerius) syrup in children with allergic skin inflammation. Patients took desloratadine syrup once a day for 28 days.
- Trial name
- NCT00817076
- Testing
- desloratadine
- Volunteers
- 40 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Probiotic Lactobacillus Rhamnosus GG for Pediatric Atopic Dermatitis
Atopic dermatitis (AD) is a multifactorial, chronic inflammatory skin disorder that results in areas of dry, itchy skin. AD affects up to 20% of children in Western societies and represents a prevalent, burdensome, and…
- Trial name
- PROPAD (NCT03863418)
- Testing
- Lactobacillus rhamnosus GG
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Federico II University
Atopic Dermatitis
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring.
- Trial name
- NCT05721937
- Testing
- Abrocitinib
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Peanut Allergy
Early Peanut Introduction: Translation to Clinical Practice
The recent finding that early introduction of peanut can prevent ~70-90% of peanut allergy is a major step towards prevention of food allergy.
- Trial name
- EPI (NCT03019328)
- Testing
- Peanut in diet
- Where
- 2 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Atopic Dermatitis (AD)
A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis
This is a Phase 2 research study testing an investigational topical cream called JYP0066 for the treatment of mild-to-moderate atopic dermatitis (eczema) in teenagers (12-17 years old) and adults.
- Trial name
- NCT07843290
- Testing
- JYP0066 4% topical cream, 3% JYP0066 topical cream, 2% JYP0066 topical cream
- Volunteers
- 160 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Atopic Dermatitis
Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study
The purpose of this study is to evaluate the continued safety and tolerability of FB-401 in subjects 2 years of age or older with mild to moderate atopic dermatitis.
- Trial name
- NCT04936113
- Testing
- FB-401
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Forte Biosciences, Inc.
Dermatitis, Atopic
Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application
The main goal of this present study is evaluate the decreasing of necessity of topic corticoids usage to control outbreaks of light to moderate atopic dermatitis by using the correct emollients.
- Trial name
- NCT01063218
- Testing
- Emollient - Cetaphil Advanced
- Where
- 2 sites in Brazil
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Galderma Brasil Ltda.
Moderate-to-severe Atopic Eczema
TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies
The TREAT NL (TREatment of ATopic eczema, the Netherlands) registry is a national registry for children and adults with moderate-to-severe atopic eczema aiming to gather data on their prescribed photo- and systemic…
- Trial name
- TREAT NL (NCT03621137)
- Testing
- No study-specific intervention
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04921345
- Testing
- Nemolizumab
- Where
- 23 sites in United States, Denmark and 3 more
- Volunteers
- 109 people
- Sponsor
- Galderma R&D
Eczema, Atopic Dermatitis
Bleach vs. Bubbles: Assessing the Impact of the Bathroom Environment on Eczema
Purpose: Evaluate the impact of cleaning the bathroom environment on the severity of eczema. Determine if part of the efficacy of bleach baths may be in cleaning the bathroom.
- Conditions
- Eczema, Atopic Dermatitis, Atopic Dermatitis and Related Conditions
- Trial name
- NCT03619161
- Testing
- Bubbles, Bleach and Bubbles
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of North Carolina, Chapel Hill
Atopic Dermatitis
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on…
- Trial name
- ADVISE MCOS (NCT05081557)
- Where
- 140 sites in Argentina, Australia and 14 more
- Volunteers
- 873 people
- Sponsor
- AbbVie
Atopic Dermatitis
Use of Complementary and Alternative Medicine in Children and Adults With Atopic Dermatitis
Complementary and alternative medicine are increasingly used all around the world and more specifically in chronic diseases such as atopic dermatitis.
- Trial name
- NCT05833880
- Testing
- Self-administered questionnaire
- Where
- France
- Volunteers
- 89 people
- Sponsor
- Central Hospital, Nancy, France
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate…
- Trial name
- AQUA (NCT06241118)
- Testing
- Amlitelimab, Topical corticosteroids, Topical tacrolimus or pimecrolimus
- Where
- 154 sites in United States, Argentina and 20 more
- Volunteers
- 464 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD)
A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis
This is a multicenter, randomized, double-blind, vehicle-controlled phase III study of MH004 Ointment with a 44-week open-label long-term safety extension period.
- Trial name
- NCT07185282
- Testing
- MH004 Ointment, Vehicle Ointment
- Where
- China
- Volunteers
- 375 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd